Obesity is silently crippling New Zealand's health system, and one controversial solution is now on the table: should taxpayers fund a $460-a-month weight loss drug? Pharmac, the agency responsible for deciding which medications Kiwis can access affordably, is grappling with this question as it seeks clinical advice on funding Wegovy (semaglutide), a medication that’s sparked both hope and debate. But here's where it gets controversial: while some see it as a costly quick fix, others argue it could save billions in long-term healthcare costs. Let’s break it down.
New Zealand ranks third-highest for adult obesity rates among OECD countries, with staggering statistics: one in three adults and one in eight children aged 2-14 are classified as obese. This isn’t just about appearance—obesity is linked to over 200 diseases, including Type 2 diabetes, which alone costs taxpayers $2.1 billion annually. Weight loss specialist Dr. Gerard McQuinlan points out that obesity isn’t a willpower issue but a hormonal one, and Wegovy targets the very hormones that regulate hunger and satiety. Without medication, 95% of people regain lost weight, often more than they started with. So, could funding Wegovy be a game-changer, or is it a bandaid on a bullet wound?
Pharmac is reviewing two applications for Wegovy funding. The first, submitted in September, targets individuals with cardiovascular disease and a BMI of 27 or higher. The second, from October, focuses on chronic weight management for those with a BMI of 30 or higher and at least one weight-related health condition. Additionally, Saxenda (liraglutide), another weight loss medication, is under assessment for people with very high BMIs. Pharmac’s David Hughes assures that expert advisors will evaluate Wegovy’s effectiveness compared to existing funded options and its broader impact on individuals, families, and the healthcare system.
Across the Tasman, Australia has already taken the plunge, announcing that Wegovy will be subsidised for patients with cardiovascular disease and a BMI of 35 or higher. This slashes the cost to AU$25 (NZ$29) per prescription, or just AU$7.70 (NZ$9) for concession card holders—a stark contrast to New Zealand’s $459.99 monthly price tag. But here’s the part most people miss: Associate Health Minister David Seymour is urging Pharmac to rethink its budget strategy, suggesting that funding drugs like Wegovy could actually save taxpayer money by reducing costs associated with obesity-related diseases. Is he onto something, or is this wishful thinking?
Dr. McQuinlan believes funding Wegovy is a no-brainer. He argues that by reducing obesity-related diseases like diabetes, the long-term savings could far outweigh the initial investment. He also dismisses concerns about drug shortages, especially once Wegovy becomes available in pill form. But not everyone is convinced. Critics worry about the financial burden and whether it’s fair to prioritise one condition over others in an already strained system.
And this is the part that sparks debate: Is obesity a personal responsibility, or should society step in to address it as a public health crisis? Should taxpayers foot the bill for a drug that some might see as optional, or is it a necessary intervention to tackle a growing epidemic? We want to hear from you—do you think funding Wegovy is a wise investment, or a costly mistake? Let us know in the comments below. One thing’s for sure: the decision Pharmac makes could reshape how we approach obesity in New Zealand for years to come.
